A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti Pd-L1 Antibody) In Combination With Adjuvant

Skip to Content

Clinical Trial Details

A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti Pd-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Objective

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer).

IRB Protocol Number
AFT-27 WO39391

Clinical Trial Categories

  • Breast Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556